secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2024-09-04T23:59:59+00:00
Accession:  0001842952-24-000070
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics appoints Dr. Karen Smith and Dr. Luke Walker to Board; board expands to 7 members
--------------------------------------------------------------------------------

- Board size increased from 5 to 7; Dr. Smith (former CMO of Jazz Pharmaceuticals) and Dr. Walker (former CMO of Harpoon Therapeutics) join.
- Dr. Smith assigned to Compensation Committee; Dr. Walker to Nominating Committee; both deemed independent under Nasdaq rules.
- Each new director received option to purchase 19,315 shares, vesting on earlier of June 13, 2025 or 2025 annual meeting.
- Dr. Smith brings over 20 years of oncology drug development (Herceptin, Vyxeos) and regulatory experience; Dr. Walker led Tukysa (tucatinib) development at Seagen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295224000070/0001842952-24-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295224000070/cntx-20240904.htm
  HTML page:      https://secwatch.observer/filing/0001842952-24-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer